Consensus $50M. The Company expects operating expenses of less than $40.0 million for the year ended December 31, 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APYX:
- Is APYX a Buy, Before Earnings?
- Hold Rating for Apyx Medical Amid Promising Ayon System and Challenging Market Conditions
- Apyx Medical submits FDA 510k to U.S. FDA for label expansion of AYON
- Needham medtech & diagnostics analysts hold analyst/industry conference call
- Apyx Medical’s Renuvion APR System: Promising Results in Facelift Surgery Study